All In Biotech

Free tool

FAERS Monitor: Akynzeo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205718 or its brand name (Akynzeo, Netupitant, Palonosetron Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,200

Serious

1,119

93% of reports

Hospitalization

620

Death reported

170

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea129
  • fatigue92
  • diarrhoea91
  • neutropenia89
  • dyspnoea75
  • vomiting72
  • death68
  • pyrexia57
  • off label use56
  • febrile neutropenia52
  • anaemia46
  • decreased appetite46
  • asthenia45
  • constipation45
  • hypotension43

Reports by year received

View as table
YearReports
20159
201618
201743
201875
2019152
2020148
2021188
202292
202378
2024113
2025148
2026136

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal5213.710.5604
neutropeniaSignal8911.59.4846
anaemiaSignal464.23.2111
hypotensionSignal433.82.885
constipationSignal453.62.783
decreased appetiteSignal463.52.679
pyrexiaSignal572.92.270
nauseaSignal1292.92.4160
vomitingSignal722.72.176
diarrhoeaSignal912.52.081
dyspnoeaSignal752.31.957
astheniaSignal452.11.625
fatigueSignal922.11.752
death681.41.17
off label use561.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.